Bayer Healthcare Company Profile
What is the competitive landscape for BAYER HEALTHCARE
BAYER HEALTHCARE has thirty-one approved drugs.
There are thirty-nine US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.
Summary for Bayer Healthcare
| US Patents: | 39 |
| Tradenames: | 26 |
| Ingredients: | 16 |
| NDAs: | 31 |
| Patent Litigation for Bayer Healthcare: | See patent lawsuits for Bayer Healthcare |
Drugs and US Patents for Bayer Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | 10,010,530 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bayer Healthcare | AMBELVIST | gadoquatrane | SOLUTION;INTRAVENOUS | 219627-005 | Jun 12, 2026 | RX | Yes | Yes | 10,722,601 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 021993-001 | Dec 12, 2006 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,774,085 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,799,505 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 11,191,766 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bayer Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | SHADE UVAGUARD | avobenzone; octinoxate; oxybenzone | LOTION;TOPICAL | 020045-001 | Dec 7, 1992 | 4,387,089 | ⤷ Start Trial |
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | 7,511,041 | ⤷ Start Trial |
| Bayer Healthcare Llc | MYCELEX | clotrimazole | CREAM;TOPICAL | 018183-001 | Approved Prior to Jan 1, 1982 | 3,660,577 | ⤷ Start Trial |
| Bayer Healthcare Llc | MYCELEX | clotrimazole | CREAM;TOPICAL | 018183-001 | Approved Prior to Jan 1, 1982 | 3,839,573 | ⤷ Start Trial |
| Bayer Healthcare Llc | SHADE UVAGUARD | avobenzone; octinoxate; oxybenzone | LOTION;TOPICAL | 020045-001 | Dec 7, 1992 | 4,522,807 | ⤷ Start Trial |
| Bayer Healthcare Llc | MYCELEX | clotrimazole | CREAM;TOPICAL | 018183-001 | Approved Prior to Jan 1, 1982 | 3,705,172 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Bayer Healthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2017246547 | ⤷ Start Trial |
| South Korea | 20170116220 | ⤷ Start Trial |
| Cuba | 20180125 | ⤷ Start Trial |
| Slovenia | 3426250 | ⤷ Start Trial |
| European Patent Office | 2493858 | ⤷ Start Trial |
| Eurasian Patent Organization | 018839 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Healthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1986495 | CR 2020 00009 | Denmark | ⤷ Start Trial | PRODUCT NAME: SEDAXAN ELLER EN TAUTOMER DERAF, FLUDIOXONIL OG METALAXYL M; NAT. REG. NO/DATE: 1-235 20191015; FIRST REG. NO/DATE: NL 15544 N 20171229 |
| 2493858 | C02493858/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: DAROLUTAMIDUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67521 19.06.2020 |
| 3106463 | C202030011 | Spain | ⤷ Start Trial | PRODUCT NAME: LAROTRECTINIB Y/O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARTICULARMENTE SULFATO DE LAROTRECTINIB QUE INCLUYE HIDROGENOSULFATO DE LAROTRECTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1385; DATE OF AUTHORISATION: 20190919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1385; DATE OF FIRST AUTHORISATION IN EEA: 20190919 |
| 1986495 | 19C1035 | France | ⤷ Start Trial | PRODUCT NAME: COMPOSITION COMPRENANT SEDAXANE OU UN TAUTOMERE DE CE COMPOSE, FLUDIOXONIL ET METALAXYL-M; NAT. REGISTRATION NO/DATE: 2180766 20181218; FIRST REGISTRATION: NL - 15544N 20171229 |
| 3106463 | CR 2020 00013 | Denmark | ⤷ Start Trial | PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923 |
| 2493858 | 301041 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DAROLUTAMIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBARE ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/20/1432 20200330 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
